MDM2 and adrenal cortex carcinoma: In fact, it has been reported that adrenocortical carcinoma cell lines are responsive to small-molecule MDM2 inhibition in vitro [104], and in preclinical studies, combined MDM2 and MEK inhibition prolongs survival of thyroid carcinoma xenograft mice [105].